Briviact is an epilepsy medicine used as an add-on to other epilepsy medicines to treat partial-onset seizures (epileptic fits starting in one specific part of the brain). It can be used in patients from the age of 2 years with partial-onset seizures with or without secondary generalisation (where the abnormal electrical activity spreads through the brain). Briviact contains the active substance brivaracetam.
Therapeutic Indication
### Therapeutic indication Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.
Therapeutic Area (MeSH)
N/AATC Code
N03AX23
ATC Item
brivaracetam
Pharmacotherapeutic Group
Antiepileptics
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| Brivaracetam | N/A | 布立西坦 |
EMA Name
Briviact (in Italy: Nubriveo)
Medicine Name
Briviact (in Italy: Nubriveo)
Aliases
N/ANo risk management plan link.
